LeMaitre Vascular insider targets Aug 6 sale of 100,000 shares

Rhea-AI Filing Summary

On Form 144, insider George W. LeMaitre filed notice to sell 100,000 common shares of LeMaitre Vascular Inc. (LMAT) through Charles Schwab on or about 6 Aug 2025. At the referenced price, the block is valued at $9.35 million and represents roughly 0.44 % of the 22.64 million shares outstanding.

The filing also lists three prior sales by the same holder between 16–20 May 2025 totaling 100,000 shares for $10.71 million in gross proceeds. The shares being disposed of were originally acquired on 2 Jun 1997 via a promissory-note transaction.

No operational or financial results are provided; the document strictly satisfies Rule 144 disclosure requirements. Nevertheless, the continued insider dispositions may create a modest share-supply overhang and could be interpreted as a signal of profit-taking ahead of the August execution date.

Positive

• None.

Negative

• Insider plans to sell an additional 100,000 LMAT shares worth $9.35 m, following 100,000 shares already sold in May 2025, indicating sustained insider selling.
• Combined 200,000-share disposition equals ~0.9 % of shares outstanding, creating a potential supply overhang and negative sentiment.

Insights

Securities Analyst

TL;DR: Repeat sale notice adds 0.44 % stock overhang; sentiment mildly negative.

This second 100 k-share Form 144 in three months brings total planned/ completed insider disposals to 200 k shares (~0.9 % of outstanding). While not large enough to alter fundamentals, persistent selling by the company’s namesake founder may pressure short-term sentiment and raises questions about insider outlook. There is no mention of hedging, gifting, or 10b5-1 plan; the market should monitor actual execution and any subsequent filings.

Corporate Governance Expert

TL;DR: Filing is routine but scale and frequency merit investor attention.

Form 144 is a procedural notice, yet the combination of size, timing, and recent prior sales indicates a deliberate liquidation program. Investors often view clustered insider sales—especially by founders—as a governance flag warranting scrutiny, even though no adverse non-public information is claimed. Absence of a disclosed 10b5-1 plan could heighten perception risk. Overall impact: modest but clearly negative for sentiment.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262	100000	9350530.00	22637522	08/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	06/02/1997	PROMISSORY NOTE	George D LeMaitre & Cornelia W. LeMaitre			100000	06/02/1997	na

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
GEORGE WELDON LEMAITRE 63 Second Avenue Burlington MA 01803	COMMON	05/16/2025	18733	3743374.00
GEORGE WELDON LEMAITRE 63 Second Avenue Burlington MA 01803	COMMON	05/19/2025	76868	6594330.00
GEORGE WELDON LEMAITRE 63 Second Avenue Burlington MA 01803	COMMON	05/20/2025	4399	374374.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many LeMaitre Vascular (LMAT) shares are slated for sale in this Form 144?

The filing covers 100,000 common shares.

What is the approximate market value of the planned LMAT share sale?

The shares are valued at $9.35 million based on the filing.

When is the insider expecting to execute the sale?

The approximate sale date is 6 August 2025.

How many LMAT shares are outstanding according to the filing?

The company lists 22,637,522 shares outstanding.

How many LMAT shares did the insider sell in the previous three months?

The insider sold 100,000 shares between 16–20 May 2025 for $10.71 million in proceeds.

What percentage of outstanding shares does the planned sale represent?

The 100,000 shares equal about 0.44 % of shares outstanding.